Drug Type CAR-T |
Synonyms Anti-CD19-Car T cell therapy, PCAR 19B |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CD19-positive B-cell acute lymphoblastic leukemia | Phase 2 | CN | 26 Jan 2022 | |
Refractory Adult Acute Lymphoblastic Leukemia | Phase 2 | CN | 26 Jan 2022 | |
Systemic Lupus Erythematosus | Phase 1 | CN | 04 Jan 2024 | |
Non-Hodgkin Lymphoma | Phase 1 | CN | 06 Sep 2021 | |
Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | CN | 30 Oct 2020 | |
Refractory B Acute Lymphoblastic Leukemia | Phase 1 | CN | 30 Oct 2020 | |
Acute lymphoblastic leukemia recurrent | Phase 1 | CN | 26 Oct 2020 |
NCT04888442 (ASH2022) Manual | Phase 1 | Pre B-cell acute lymphoblastic leukemia CD19 Positive | 9 | nvrlolponk(fjeburulpp) = czkhxvbyuu apucudxmgw (xwztlnxkdl ) View more | Positive | 15 Nov 2022 |